CONTENTS

PREFACE  xiii

INTRODUCTION  xv
Background History on Clinical Research Standards  xv

GLOSSARY  xvii

CHAPTER 1  GOOD CLINICAL PRACTICE AND THERAPEUTIC PRODUCT DEVELOPMENT  1
1.1 Good Clinical Practice in Clinical Research  2
  1.1.1 Definition  2
  1.1.2 GCP Compliance  2
  1.1.3 GCP Objectives  2
  1.1.4 Principles of ICH GCP  3
    Clinical Trial Conduct  3
    Risk Assessment  3
    Subject’s Rights and Safety  3
    Background Information  3
    Clinical Trial Protocol  3
    Ethics Review and Approval  3
    Medical Care of Trial Subject  4
    Qualifications of Clinical Trial Personnel  4
    Informed Consent Process  4
    Data Management  4
    Patient Confidentiality  4
    Investigational Product Manufacturing, Handling, and Storage  4
    Quality Assurance  4
  1.1.5 GCP Applicability  5
1.2 Role of the Sponsor of a Clinical Investigation  6
  1.2.1 GCP: Responsibilities of a Sponsor of a Clinical Trial  6
  1.2.2 Essential Documents for the Clinical Trial  9
    Retention of the Essential Documents for the Clinical Trial  9
    Archiving of the Essential Documents for the Clinical Trial  9
    After Discontinuation of Development  9
    Notification  10
    Transfer of Data Ownership  10
    Records Retention  10
  1.2.3 Investigator Selection  10
    Investigator’s Qualifications  10
    Resources at the Investigator’s Site  11
    Protocol and Investigator’s Brochure  11
    Agreement with the Investigator/Institution  11
CONTENTS

1.2.4 Allocation of Responsibilities 11
1.2.5 Compensation to Subjects and Investigators 12
  Compensation to Subjects for Trial-Related Injuries 12
  Other types of Compensation to Trial Subjects 12
1.2.6 Financing 12
1.2.7 Notification/Submission to Regulatory Authorities 13
1.2.8 Confirmation of Review by IRB/IEC 13
1.2.9 Information on Investigational Products 14
1.2.10 Manufacturing, Packaging, Labelling, and Coding
  Investigational Products 14
  Characterization, Manufacturing, and Labeling of the
  Investigational Product 14
  Storage Conditions 14
  Packaging of the Investigational Product 14
  Coding and Decoding of the Investigational Product 14
  Investigational Product Changes and Bioequivalence Studies 15
1.2.11 Supplying and Handling Investigational Products 15
  Supply 15
  Investigational Product Records 15
1.2.12 Record Access 16
  Verification of Patient Consent to Record Access 16
1.2.13 Safety Information 16
  Safety Issues 16
  Communication of Safety Issues 16
1.2.14 Adverse Drug Reaction Reporting 17
  Serious Unexpected Adverse Drug Reactions 17
  SAE Reporting Compliance 17
  Safety Updates and Periodic Reports 17
1.2.15 Monitoring 17
  Purposes 18
  Selection and Qualifications of Monitors 18
  Monitoring Strategies 19
  Monitor’s Responsibilities 19
  Monitoring Procedures 21
  Monitoring Report 21
1.2.16 Audit 21
  Purposes 22
  Selection and Qualifications of Auditors 22
  Auditing Procedures 22
  Site Selection Criteria for Inspection 22
  Reporting of Findings 23
  Audit Certificate 23
1.2.17 Noncompliance 23
1.2.18 Premature Termination or Suspension of a Trial 24
1.2.19 Clinical Trial/Study Reports 24
1.2.20 Multicenter Trials 24

1.3 Role of the Institutional Review Board/Independent Ethics Committee (IRB/IEC) 25
  1.3.1 Responsibilities 25
  Document Gathering 25
  Review of Documentation 26
CONTENTS

1.3.2 Considerations for Review 26
1.3.3 Additional Information to be Provided To Subjects 26
    Nontherapeutic Trials 26
    Emergency Situations 26
    Payment to Study Subjects 27
    Payment Information in the Consent Form 27
    Composition, Functions, and Operations 27
    IRB/IEC Standard Operating Procedures 28
    Records 29
1.4 Roles and Responsibilities of the Clinical Trial Investigator 29
    1.4.1 Investigator’s Qualifications and Agreements 29
    1.4.2 Adequate Resources 30
    1.4.3 Medical Care of Trial Subjects 30
    1.4.4 Communication with IRB/IEC 31
    1.4.5 Compliance with Protocol 31
    1.4.6 Investigational Product(s) 32
    1.4.7 Randomization Procedures and Unblinding 33
    1.4.8 Informed Consent of Trial Subjects 33
    1.4.9 Records and Reports 37
        Safety Reporting 38
    1.4.10 Progress Reports 38
    1.4.11 Premature Termination or Suspension of a Trial 38
1.5 Clinical Trial Protocol and Protocol Amendments 39
    1.5.1 Contents of Trial Protocol 39
    1.5.2 Investigator’s Brochure 42
        Introduction 42
        General Considerations 43
        Contents of the Investigator’s Brochure 43

CHAPTER 2  THERAPEUTIC PRODUCTS CLINICAL DEVELOPMENT IN THE UNITED STATES 47

2.1 Drug Discovery 47
2.2 Preclinical Development 47
    2.2.1 In Vitro Testing 47
    2.2.2 In Vivo Testing (Animal Testing) 48
2.3 Clinical Development 48
2.4 FDA Considerations for Drug Development 50
    2.4.1 Pre-IND Meeting 50
    2.4.2 End of Phase II Meeting 50
    2.4.3 Pre-NDA Meeting 51
2.5 Phase IV, Postmarketing Surveillance and GCP 51
2.6 Quality Assurance in Clinical Research 52
2.7 FDA Inspectational Background and Data 53
    2.7.1 The FDA and GCP 53
    2.7.2 FDA: Responsibilities of the Sponsor (Subpart D 21 CFR 312.50 to 21 CFR 312.58) 54
    2.7.3 FDA: Responsibilities of the Investigator – (Subpart D 21 CFR 312.50 to 21 CFR 312.58) 56
        Investigator Recordkeeping and Record Retention 56
        Investigator Reports 57
        Assurance of IRB Review 57
CONTENTS

Inspection of Investigator’s Records and Reports 57
Handling of Controlled Substances 58
Disqualification of a Clinical Investigator 58

2.7.4 FDA: Responsibilities of the Institutional Review Board (21 CFR Part 56) 59
Circumstances in Which IRB Review is Required 59
Exemptions from IRB Requirement 59
Waiver of IRB Requirement 60
IRB Membership 60
IRB Functions and Operations 61
IRB Review of Research 61
Expedited Review Procedures for Certain Kinds of Research Involving No More than Minimal Risk and for Minor Changes in Approved Research 62
Criteria for IRB Approval of Research 63
Review by Institution 64
Suspension or Termination of IRB Approval of Research 64
Cooperative Research 64
IRB Records 64
Lesser Administrative Actions for Noncompliance 65
Disqualification of an IRB or an Institution 65
Public Disclosure of Information Regarding Revocation 66
Reinstatement of an IRB or an Institution 66
Actions Alternative or Additional to Disqualification 66

2.8 FDA Bioresearch Monitoring Program 67
2.8.1 Clinical Trials Inspectional Background 67
2.8.2 Program Objectives 67
2.8.3 Types of Inspections Performed by the FDA 67
Routine Inspections 67
Directed (for Cause) Inspections 68
Classification of Inspections 68
2.8.4 Who Is Inspected? 68
2.8.5 Implementation of the FDA’s Application Integrity Policy 68
2.8.6 BIMO Inspections for Clinical Trials 69
2.8.7 The FDA and International GCP Inspections 74
Criteria for International Sites Selection for Inspection 76

CHAPTER 3 THE INSPECTION PREPARATION 77

3.1 Conduct of an Internal GCP Inspection: Quality Assurance Inspection 77
3.2 Steps to Prepare for the Internal QA Inspection 78
3.2.1 Inspection of the Trial Master File (TMF) 78
3.2.2 Inspection of an Investigator Site 79
3.2.3 Inspection of the Contract Research Organization (CRO) 79
3.2.4 Inspection of Clinical Laboratories 79
3.3 The GCP Quality Assurance Unit 80
3.3.1 Scope of an Internal GCP Inspection 80
3.3.2 Outcome of an Internal Inspection 81
3.4 Steps to Prepare for the Regulatory Inspection 82
3.5 Clinical Investigator Inspections Preparation 84
3.6 What to Do When an Investigator Site FDA Inspection is Announced 84
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.7 Sponsor’s Inspection Preparation</td>
<td>86</td>
</tr>
<tr>
<td>3.8 What to Do When Sponsors FDA Inspector Arrive Unannounced</td>
<td>87</td>
</tr>
<tr>
<td>3.9 The Institutional Review Board Inspections Preparation</td>
<td>88</td>
</tr>
<tr>
<td>3.9.1 Central IRBs</td>
<td>90</td>
</tr>
<tr>
<td>3.10 What to Do When an IRB FDA Inspection is Announced</td>
<td>91</td>
</tr>
<tr>
<td>3.11 The Investigator Site Inspection</td>
<td>92</td>
</tr>
<tr>
<td>3.11.1 Objective of an FDA Investigator Site Inspection</td>
<td>92</td>
</tr>
<tr>
<td>3.11.2 Dynamics of a Clinical Investigator’s Inspection (Scope)</td>
<td>93</td>
</tr>
<tr>
<td>3.12 Investigator’s Responsibilities</td>
<td>93</td>
</tr>
<tr>
<td>3.13 Types of Clinical Investigator Site Inspections</td>
<td>101</td>
</tr>
<tr>
<td>3.14 Inspectional Procedures</td>
<td>102</td>
</tr>
<tr>
<td>3.14.1 The Investigator Site Documentation and Organization</td>
<td>102</td>
</tr>
<tr>
<td>3.14.2 The Sponsor’s Role in the Investigator Site Audit</td>
<td>103</td>
</tr>
<tr>
<td>3.14.3 The Clinical Investigator Site Inspection Step by Step: The Day</td>
<td></td>
</tr>
<tr>
<td>of the Inspection</td>
<td>103</td>
</tr>
<tr>
<td>3.15 FDA Audit Procedures for Investigative Sites</td>
<td>104</td>
</tr>
<tr>
<td>3.15.1 Authority and Administration</td>
<td>104</td>
</tr>
<tr>
<td>3.15.2 Inspecting the Protocol</td>
<td>106</td>
</tr>
<tr>
<td>3.15.3 Inspecting Subjects’ Records</td>
<td>106</td>
</tr>
<tr>
<td>3.15.4 Inspecting Other Study Records</td>
<td>109</td>
</tr>
<tr>
<td>3.15.5 Inspecting the Consent of Human Subjects</td>
<td>109</td>
</tr>
<tr>
<td>3.15.6 Inspecting the Institutional Review Board Documentation</td>
<td>110</td>
</tr>
<tr>
<td>3.15.7 Inspecting the Sponsor’s Documentation and Communications</td>
<td>111</td>
</tr>
<tr>
<td>3.15.8 Inspecting the Investigational Product (Test Article Accountability)</td>
<td>112</td>
</tr>
<tr>
<td>3.15.9 Inspecting the Records Retention Process</td>
<td>113</td>
</tr>
<tr>
<td>3.15.10 Inspecting Electronic Records and Signatures</td>
<td>113</td>
</tr>
<tr>
<td>3.15.11 Inspecting Device Studies</td>
<td>115</td>
</tr>
<tr>
<td>3.16 FDA Inspections of International Clinical Trial Sites</td>
<td>115</td>
</tr>
<tr>
<td>3.17 The Audit Report and Form 483</td>
<td>116</td>
</tr>
<tr>
<td>3.17.1 The Exit Interview</td>
<td>116</td>
</tr>
<tr>
<td>3.17.2 What Is Form 483?</td>
<td>117</td>
</tr>
<tr>
<td>3.17.3 Responding to a Form 483</td>
<td>119</td>
</tr>
<tr>
<td>3.17.4 The Follow-up</td>
<td>121</td>
</tr>
<tr>
<td>3.17.5 Warning Letter</td>
<td>121</td>
</tr>
<tr>
<td>3.17.6 Regulatory Actions Against Clinical Investigators</td>
<td>124</td>
</tr>
<tr>
<td>Notice of Initiation of Disqualification Proceeding and Opportunity to</td>
<td></td>
</tr>
<tr>
<td>Explain (NIDPOE) (312.70)</td>
<td>124</td>
</tr>
<tr>
<td>What is a Disqualification of an Investigator?</td>
<td>125</td>
</tr>
<tr>
<td>What is the Consent Agreement?</td>
<td>125</td>
</tr>
<tr>
<td>3.17.7 The Clinical Hold</td>
<td>125</td>
</tr>
<tr>
<td>Issue of the Clinical Hold</td>
<td>126</td>
</tr>
<tr>
<td>Scope of the Clinical Hold</td>
<td>126</td>
</tr>
<tr>
<td>Meaning of the Clinical Hold</td>
<td>126</td>
</tr>
<tr>
<td>Extent of the Clinical Hold</td>
<td>126</td>
</tr>
<tr>
<td>Lift of the Clinical Hold</td>
<td>127</td>
</tr>
<tr>
<td>3.17.8 Reinstatement of Disqualified Investigators</td>
<td>127</td>
</tr>
<tr>
<td>3.17.9 Regulatory Action Against Companies or Persons (Not Investigators): Debarment</td>
<td>127</td>
</tr>
</tbody>
</table>
CONTENTS

CHAPTER 4  ANALYSIS OF WARNING LETTERS  129
4.1 Analysis of Warning Letters Issued to Clinical Investigators  129
   4.1.1 Most Common Findings of Investigator Site Inspections  129
   Findings Relating to Patient Information and Consent Form and
   Process  129
   Findings Relating to Investigator’s Supervision of the Clinical
   Trial  133
   Findings Relating to Protocol Adherence  135
   Findings Relating to Records in Clinical Trials  138
   Findings Relating to the Investigational Product in Clinical Trials  142
   Findings Relating to the Reporting of Adverse Events  143
   Findings Relating to the Institutional Review Board’s
   Approvals and Reporting  146
   Findings Relating to the Investigator Acting in a Dual Role of
   Sponsor–Investigator  148
4.2 An Analysis of Warning Letters Issued to Clinical Trial Sponsors  149
   4.2.1 Most Common Sponsors of Clinical Investigations Findings  149
   Findings Relating to the Sponsor’s Responsibilities to Ensure
   Proper Monitoring of a Clinical Trial  149
   Findings Relating to the Sponsor’s Responsibilities for the
   Investigational Product  152
   Findings Relating to the Sponsor’s Records of a Clinical
   Investigation  152
   Findings Relating to the Sponsor Obtaining an IND to Conduct
   a Study  153
   Findings Relating to the Sponsor’s Responsibilities to Secure
   Agreements Within Parties  153
4.3 Analysis of Warning Letters Issued to Institutional Review Boards  154
   4.3.1 Most Common Institutional Review Board Findings  155
   Findings Relating to IRB Operational Procedures  155
   Findings Relating to IRB Initial and Continuing Review Process  159
   Findings Relating to IRB Recordkeeping and Retention  160
   Findings Relating to IRB Composition and Membership  162
   Findings Relating to IRB Review Process  163
   Findings Relating to IRB Review Process of Special
   Populations in Clinical Trials  165
   Administrative Actions to IRBs  165
   Reinstatement of a Disqualified IRB  166
   Conclusions on the Findings  167

CHAPTER 5  FRAUD AND MISCONDUCT IN CLINICAL RESEARCH  169
5.1 What Type of Data is Falsified?  170
5.2 How is Data Falsified?  171
5.3 Why is Data Falsified?  172
5.4 Who Falsified the Data?  172
5.5 What Can be Done to Detect Fraud?  173
5.6 How Do We Prevent Fraud?  173
APPENDIX A  SOME ANSWERS TO THE MOST PROBLEMATIC QUESTIONS IN COMPLIANCE  177

How Can an Investigator Site Demonstrate That the Proper Consent Process Was Followed? 177
How Does One Demonstrate that a Subject Understood the Consent Information? 177
How Does One Demonstrate that all the Clinical Trial Procedures were Followed? 178
How Does One Demonstrate Principal Investigator Personal Involvement in the Supervision of Clinical Trial Activities? 178
Why Follow Standard Operating Procedures in Clinical Trials? 178

APPENDIX B  GUIDANCE FOR INDUSTRY—E6 GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDANCE  179

Introduction 181

APPENDIX C  WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS  225

A. Introduction 225
B. Basic Principles for all Medical Research 226
C. Additional Principles for Medical Research Combined with Medical Care 228

APPENDIX D  NUREMBERG CODE  231

APPENDIX E  THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH  233

Part A: Boundaries Between Practice and Research 235
Part B: Basic Ethical Principles 236
Part C: Applications 238

INDEX 245